Announcement • May 05
Bioceres Crop Solutions Corp. to Report Q3, 2026 Results on May 12, 2026 Bioceres Crop Solutions Corp. announced that they will report Q3, 2026 results at 12:30 PM, US Eastern Standard Time on May 12, 2026 Announcement • Jan 12
Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026 Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026. Location: 1290 avenue of the americas, ny 10104, new york United States Announcement • Oct 31
Bioceres Crop Solutions Corp. announced delayed 20-F filing On 10/30/2025, Bioceres Crop Solutions Corp. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Oct 30
Bioceres Crop Solutions Corp. to Report Q1, 2026 Results on Nov 13, 2025 Bioceres Crop Solutions Corp. announced that they will report Q1, 2026 results Pre-Market on Nov 13, 2025 Announcement • Oct 02
Bioceres Crop Solutions Corp. Announces Resignation of Noah Kolatch as A Member of the Board of Directors, Effective September 30, 2025 Bioceres Crop Solutions Corp. informs that, effective September 30, 2025, Noah Kolatch resigned as a member of the board of directors of the Company, in connection with the delivery of the reservation of rights letter delivered to the Company by Jasper Lake, through counsel, dated September 25, 2025, a copy of which is filed herewith as Exhibit 99.1. In response to the Kramer Letter, the Company delivered a reservation of rights letter to Jasper Lake on September 30, 2025, disputing that any Events of Default have occurred under the Note Purchase Agreements and reinforcing that it is in the best interest of the Company and all of its stakeholders to engage in a productive dialogue with Jasper Lake to address any legitimate concern it may have, a copy of which is filed herewith as Exhibit 99.2. The Company is committed to maintaining its focus on improving its commercial and financial performance and delivering innovative solutions to the agricultural market. Announcement • Sep 03
Bioceres Crop Solutions Corp. to Report Q4, 2025 Results on Sep 09, 2025 Bioceres Crop Solutions Corp. announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Sep 09, 2025 Announcement • Aug 21
Bioceres Crop Solutions Corp. Announces CFO Changes, Effective from August 20, 2025 Bioceres Crop Solutions Corp. announced that the board of directors (the “Board”) of the Company and Mr. Enrique Lopez Lecube, Chief Financial Officer, have agreed to initiate a transition in the Company’s financial leadership. Effective August 20, 2025, Mr. Lopez Lecube will step down from his appointment as Chief Financial Officer, and Scott Crocco, a member of the Board, will act solely to assist in managing the finance departments of the Company on an interim basis. The Company has initiated a market search for a new Chief Financial Officer. During his tenure, Mr. Lopez Lecube has made significant contributions to the Company’s financial strategy and expansion. Announcement • Jun 20
Bioceres Crop Solutions Announces Changes to Board of Directors, Effective from June 24, 2025 Bioceres Crop Solutions Corp. announced changes to the composition of its Board of Directors. Noah Kolatch and Scott Crocco are being appointed to the Company's Board of Directors with effect from June 24, 2025. Noah Kolatch is a Principal at Jasper Lake LLC, a family investment office that invests across public and private markets. Prior to joining Jasper Lake, Mr. Kolatch was a Partner at Solel Partners, a Boston-based investment firm focused on public equity and credit investments. Mr. Kolatch graduated summa cum laude from Columbia College with a BA in biochemistry. Scott Crocco is a seasoned executive with over three decades of experience in finance and operations across public and private companies. Mr. Crocco was CFO of Air Products & Chemicals Inc, where he led corporate restructuring and portfolio transformation, and later served as Chief Financial Officer of Imperial Dade, a private equity-backed distributor. Mr. Crocco holds a BS in Electrical Engineering from Bucknell University and an MBA from Cornell University. Gloria Montaron Estrada, who has served as a Director since February 2019, and Keith McGovern, who has served as a Non-Executive Director since July 2022, have each resigned from the Company's Board of Directors with effect from June 24, 2025. Enrique Lopez Lecube, the Company's Chief Financial Officer and member of the Company's senior management team, will rotate off the Company's Board of Directors. The resulting vacancy will be filled by Milen Marinov, the Company's Chief Commercial Officer and member of the Company's senior management team. These changes will also be effective from June 24, 2025. Announcement • May 10
Bioceres Crop Solutions Corp. to Report Q3, 2025 Results on May 21, 2025 Bioceres Crop Solutions Corp. announced that they will report Q3, 2025 results on May 21, 2025 Announcement • Mar 12
Bioceres Crop Solutions and ProFarm Group's Platform, Rinotec, Receives Federal Registration from the U.S. Environmental Protection Agency Bioceres Crop Solutions and ProFarm Group announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA’s assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regions, offering growers a powerful alternative that reduces reliance on traditional chemical pesticides. These approvals highlight the product’s strong efficacy profile and position Bioceres Crop Solutions to capitalize on growing market opportunities in two of the world’s largest agricultural economies. Announcement • Mar 06
Bioceres Crop Solutions Secures Patent Protection for Hb4 Wheat in the U.S. Until 2042 Bioceres Crop Solutions Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its first event-specific patent covering the HB4 Wheat, IND-OO412-7. This approval is the first of four potential patents the company is pursuing for HB4 Wheat in the United States, securing protection for this technology and associated production system until 2042. HB4 wheat offers improved tolerance to drought and enhanced weed management options compared to conventional wheat. The technology has already been approved by the USDA for cultivation and by the FDA for food and feed use in the United States. The U.S. is the fourth largest wheat producer, with nearly 40 million acres harvested in the most recent marketing year. In alignment with the company's commitment to responsible commercialization, Bioceres Crop Solutions will adhere to the U.S. Wheat Associates' (USW) "Wheat Industry Principles for Biotechnology Commercialization" developed with the National Association of Wheat Growers (NAWG). These principles include maintaining fluent dialogue with USW/NAWG, securing regulatory approvals for food and feed in major wheat export markets, establishing tolerance thresholds for low level presence, providing trait detection tests, and ensuring product stewardship through education, outreach and a certified seed value capture model. The commercial rollout of HB4 wheat in the U.S. will follow a broad licensing approach, consistent with the company's recently announced go-to-market strategy for its HB4 technology. Announcement • Feb 06
Bioceres Crop Solutions Corp. Provides Earnings Guidance for the Second Quarter Ended December 31, 2024 Bioceres Crop Solutions Corp. provided earnings guidance for the second quarter ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first half of the year. Announcement • Jan 30
Bioceres Crop Solutions Corp. to Report Q2, 2025 Results on Feb 12, 2025 Bioceres Crop Solutions Corp. announced that they will report Q2, 2025 results on Feb 12, 2025 Reported Earnings • Nov 12
First quarter 2025 earnings released: US$0.086 loss per share (vs US$0.073 loss in 1Q 2024) First quarter 2025 results: US$0.086 loss per share (further deteriorated from US$0.073 loss in 1Q 2024). Revenue: US$92.6m (down 20% from 1Q 2024). Net loss: US$5.40m (loss widened 18% from 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Oct 31
Bioceres Crop Solutions Corp. to Report Q1, 2025 Results on Nov 12, 2024 Bioceres Crop Solutions Corp. announced that they will report Q1, 2025 results on Nov 12, 2024 Announcement • Oct 04
Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024 Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024. Location: 1290 avenue of the americas, new york, 10104, new york United States Buy Or Sell Opportunity • Oct 01
Now 21% overvalued Over the last 90 days, the stock has fallen 30% to €6.95. The fair value is estimated to be €5.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.6% per annum. Earnings are also forecast to grow by 36% per annum over the same time period. New Risk • Sep 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (0.7% net profit margin). Reported Earnings • Sep 11
Full year 2024 earnings released: EPS: US$0.051 (vs US$0.30 in FY 2023) Full year 2024 results: EPS: US$0.051 (down from US$0.30 in FY 2023). Revenue: US$464.8m (up 11% from FY 2023). Net income: US$3.20m (down 83% from FY 2023). Profit margin: 0.7% (down from 4.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Aug 27
Bioceres Crop Solutions Corp. to Report Q4, 2024 Results on Sep 10, 2024 Bioceres Crop Solutions Corp. announced that they will report Q4, 2024 results on Sep 10, 2024 Reported Earnings • May 14
Third quarter 2024 earnings released: EPS: US$0.15 (vs US$0.45 in 3Q 2023) Third quarter 2024 results: EPS: US$0.15 (down from US$0.45 in 3Q 2023). Revenue: US$84.0m (down 9.7% from 3Q 2023). Net income: US$9.30m (down 67% from 3Q 2023). Profit margin: 11% (down from 30% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Announcement • May 08
Bioceres Crop Solutions Corp. Announces Brazil’s Approval of New Generation Bio-Insecticide Bioceres Crop Solutions Corp. announced the approval by Brazil’s Ministry of Agriculture and Livestock (MAPA- Ministério da Agricultura e Pecuária) of three new bio-insecticidal/bio-nematicidal solutions derived from inactivated cells of the company’s proprietary Burkholderia platform. The approval represents a significant regulatory milestone in the Brazilian market, marking the first endorsement of biological products formulated from fully inactivated microorganisms. Bioceres’ most advanced bio-control solutions leverage the metabolites of inactivated microorganisms, resulting in products that demonstrate heightened effectiveness, precision, shelf-life, and formulation stability, as well as greater consistency in their mode of action compared to live microbes. Moreover, non-living bacteria-based products can be formulated with increased potency and at much lower costs, nearing cost parity to less favorable present-day chemical alternatives. Bioceres products based on Burkholderia-derived metabolites were first registered in the United States in 2014 and have since been commercialized in Mexico, Peru, Chile, Turkey, and parts of Africa. In the United States alone, they are used as nematicidal and insecticidal seed treatment on more than 4 million hectares (>10 million acres) of corn, cotton and soybeans, effectively replacing abamectin in seed treatments, while also boosting the control of soil-dwelling insect pests that are typically controlled by neonicotinoids, pyrethroids, and organophosphates. Announcement • May 03
Bioceres Crop Solutions Corp. to Report Q3, 2024 Results on May 14, 2024 Bioceres Crop Solutions Corp. announced that they will report Q3, 2024 results on May 14, 2024 Reported Earnings • Feb 11
Second quarter 2024 earnings released: EPS: US$0.002 (vs US$0.13 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.002 (up from US$0.13 loss in 2Q 2023). Revenue: US$140.3m (up 48% from 2Q 2023). Net income: US$100.0k (up US$8.26m from 2Q 2023). Profit margin: 0.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Board Change • Jan 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Ari Freisinger was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 26
Bioceres Crop Solutions Corp. to Report Q2, 2024 Results on Feb 08, 2024 Bioceres Crop Solutions Corp. announced that they will report Q2, 2024 results on Feb 08, 2024 Announcement • Oct 12
Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023 Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023, at 10:00 US Eastern Standard Time. Location: 1290 Avenue of the Americas New York United States Agenda: To consider the report of the Board of Directors of the Company and the report of the independent auditors of the Company’s consolidated financial statements for the financial year ended June 30, 2023 and to approve the Company’s consolidated financial statements for the financial year ended June 30, 2023; to consider and vote upon a proposal to appoint the seven directors; and to consider and vote upon the ratification of appointment of Price Waterhouse & Co. S.R.L. as the independent registered public accounting firm of the Company. Reported Earnings • Sep 12
Full year 2023 earnings released: EPS: US$0.26 (vs US$0.17 loss in FY 2022) Full year 2023 results: EPS: US$0.26 (up from US$0.17 loss in FY 2022). Revenue: US$419.8m (up 28% from FY 2022). Net income: US$16.7m (up US$23.9m from FY 2022). Profit margin: 4.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Announcement • Aug 31
Bioceres Crop Solutions Corp. to Report Q4, 2023 Results on Sep 11, 2023 Bioceres Crop Solutions Corp. announced that they will report Q4, 2023 results on Sep 11, 2023 Valuation Update With 7 Day Price Move • May 17
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €10.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past year. Reported Earnings • May 11
Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.16 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.45 (up from US$0.16 loss in 3Q 2022). Revenue: US$93.6m (up 37% from 3Q 2022). Net income: US$28.1m (up US$34.6m from 3Q 2022). Profit margin: 30% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Announcement • Jan 27
Bioceres Crop Solutions Corp. to Report Q2, 2023 Results on Feb 09, 2023 Bioceres Crop Solutions Corp. announced that they will report Q2, 2023 results on Feb 09, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Natalia Zang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 11
First quarter 2023 earnings released: EPS: US$0.011 (vs US$0.021 in 1Q 2022) First quarter 2023 results: EPS: US$0.011 (down from US$0.021 in 1Q 2022). Revenue: US$127.1m (up 92% from 1Q 2022). Net income: US$498.3k (down 43% from 1Q 2022). Profit margin: 0.4% (down from 1.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Reported Earnings • Sep 09
Full year 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in FY 2021) Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.17 loss in FY 2021). Revenue: US$334.8m (up 62% from FY 2021). Net loss: US$7.33m (loss widened 6.7% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Reported Earnings • May 13
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: US$69.5m (up 96% from 3Q 2021). Net loss: US$6.49m (loss widened 450% from 3Q 2021). Over the next year, revenue is forecast to grow 8.7%, compared to a 6.4% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Mar 10
Now 22% undervalued Over the last 90 days, the stock is up 4.2%. The fair value is estimated to be US$15.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last year. Board Change • Mar 05
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 11
First quarter 2022 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$66.9m (up 59% from 1Q 2021). Net income: US$875.2k (up US$7.85m from 1Q 2021). Profit margin: 1.3% (up from net loss in 1Q 2021). Reported Earnings • Sep 11
Full year 2021 earnings released The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$209.5m (up 22% from FY 2020). Net loss: US$6.60m (down 297% from profit in FY 2020). Board Change • Jul 29
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. 
